HAART and changes of epidemiology, treatment and prognosis of HIV-positive patients with Kaposi's sarcoma and lymphoma;HAART et modification de l'épidémiologie, du traitement et du pronostic des patients séropositifs pour le VIH atteints de maladie de Kaposi et de lymphome

Bulletin du Cancer

Volumn 90, Issue 5, 2003, Pages 419-425

  Gabarre, Jean ^a   Bossi, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; KAPOSI SARCOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PREVALENCE; PROGNOSIS; REVIEW; SERODIAGNOSIS; B CELL LYMPHOMA; INCIDENCE; SURVIVAL; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; INCIDENCE; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; PROGNOSIS; SARCOMA, KAPOSI; SURVIVAL;

EID: 0041705345     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Gulick R, Mellors J, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
2. Collier A, Coombs R, Schoenfeld D, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011-7.
3. Hammer S, Squires K, Hugues M, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in patients with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
4. Palella F, Delaney K, Moorman A, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus. N Engl J Med 1998; 338: 853-8.
5. Chang Y, Cesarman E, Pessin M, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-9.
6. Beral V, Peterman T, Berkelman B, Jaffe H. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335: 123-8.
7. Safai B, Johnson K, Myskowski P, Koziner B, Yang SY, Cunningham-Rundles S, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 744-50.
8. Beral V, Jaffe H, Weiss R. Cancer surveys: cancer, HIV, and AIDS. Eur J Cancer 1991; 27: 1057-8.
9. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000; 342: 1027-38.
10. Buchbinder SP, Holmberg SD, Scheer S, Colfax G, O'Malley P, Vittinghoff E. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr 1999; 21: S23-6.
11. Jones J, Hanson D, Dworkin M, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr 1999; 21: S11-21.
12. Jacobson L, Yamashita T, Derels R, Margolick JB, Chmiel JS, Kingsley LA, et al. Impact on potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals. J Acquir Immune Defic Syndr 1999; 21: S34-41.
13. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92; 1823-30.
14. Aboulafia D. The epidemiologic, pathologic, and clinical feature of AIDS-associated pulmonary Kaposi's sarcoma. Chest 2000; 117: 1128-45.
15. Ives N, Gazzard B, Easterbtook P. The changing pattern of AIDS-defining illness with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001; 42: 134-9.
16. Catrelan A, Trevenzoli M, Aversa S. Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2002; 3: 451-62.
17. Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthe H, de Truchis P, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 2000; 14: 987-93.
18. Holkova B, Takeshita K, Cheng D, Volm M, Wasserheit C, Demopoulos R, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001; 19: 3848-51.
19. Tam H, Zhang Z, Jacobson L, Margolick J, Chmiel J, Rinaldo C, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98: 916-22.
20. Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type-1-infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76: 2634-40.
21. Mocroft AJ, Lundgren JD, d'Armino Monforte A, Ledergerber B, Barton SE, Vella S, et al. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol 1997; 26: 400-7.
22. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer 1999; 12: 481-5.
23. Gabarre J, Raphael M, Lepage E, Martin A, Oksenhendler E, Xerri L, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med 2001; 111: 704-11.
24. Biggar RJ, Engels EA, Frisch M, Goedert JJ. Risk of T-cell lymphomas in persons with AIDS. J Acquir Immune Defic Syndr 2001; 26: 371-6.
25. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000; 27: 442-53.
26. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA 1999; 282: 2220-6.
27. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15: 629-33.
28. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-4.
29. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933-42.
30. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339-44.
31. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-12.
32. Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14: 133-40.
33. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1641-8.
34. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-8.
35. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-63.
36. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112: 909-15.
37. Gerard L, Galicier L, Maillard A, Boulanger E, Quint L, Matheron S, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30: 478-84.
38. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretrovital therapy. AIDS 2001; 15: 1483-91.
39. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
40. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002; 159: 149-53.
41. Sparano JA, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15: 50-7.
42. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531-6.
43. Spina M, Vaccher E, Juzbasic S, Milan I, Nasti G, Talamini R, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001; 92: 200-6.
44. Bi J, Espina BM, Tulpule A, Boswell W, Levine AM. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001; 28: 416-21.
45. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000; 355: 1071-2.
46. Krishnan A, Molina A, Zaia J, Nademanee A, Kogut N, Rosenthal J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98: 3857-9.
47. Hoffmann C, Tabtizian S, Wolf E, Eggers C, Stoeht A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15: 2119-27.
48. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11: 1725-30.
49. Spina M, Vaccher E, Nasti G, Tirelli U. Human immunodeficiency virus-associated Hodgkin's disease. Semin Oncol 2000; 27: 480-8.
50. Spina M, Gabarre J, Rossi G, Fasan M, Schiantatelli C, Nigra E, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100: 1984-8.